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Abstract
Background: We carried out a systematic review and meta-analysis with the aim to evaluate the efficacy of long-
acting bronchodilators on exercise capacity in COPD patients.
Methods: The endpoints were the efficacy of long-acting bronchodilators (altogether, and by single classes)
vs. placebo in modifying endurance time (ET), inspiratory capacity (IC) and dyspnea during exercise, taking into
consideration the outcomes according to different patients’ inclusion criteria and exercise methodology.
Results: Twenty-two studies were deemed eligible for analysis. Weighted mean increase in ET resulted of 67 s
(95% CI ranges from 55 to 79). For isotime IC and dyspnea during exercise, weighted improvements were 195
ml (162–229), and − 0.41 units (− 0.56 to − 0.27), respectively. The increase in trough IC was 157 ml (138–175). We
found a trend in favour of LAMA compared to LABA in terms of ET. In the 11 studies which reported a value of
functional residual capacity > 120% as inclusion criterion, weighted mean increase in endurance time was 94 s
(65 to 123); however we did not find any significant correlation between ET and mean trough IC (P: 0.593). The
improvement of ET in the 5 studies using walking as exercise methodology resulted of 58 s (− 4 to 121).
Conclusions: Long-acting bronchodilators improve exercise capacity in COPD. The main effect of long-acting
bronchodilators seems to be a decrease of basal IC rather than a modification of dynamic hyperinflation during
exercise. The efficacy in terms of endurance time seems higher in studies which enrolled patients with hyperinflation,
with a similar efficacy on walking or cycling.
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Background
In patients with chronic obstructive pulmonary disease
(COPD) exercise limitation is mainly due to dynamic
hyperinflation [1], even if the contribution of other
factors, such as an imbalance between respiratory and
locomotor muscles for limited energy supply [2], limb
muscle dysfunction [3], and co-morbidities (e.g., left ven-
tricle diastolic dysfunction) [4] can play a significant
role. Reduced daily activity has been well documented in
COPD patients, resulting from both respiratory and
non-respiratory clinical conditions associated with the
disease [5]. An evaluation performed by multisensory
armband confirmed that daily physical activity is mainly
associated with dynamic hyperinflation, regardless of
COPD severity [6]. It was clearly proved that exercise
capacity and daily activity are closely associated with life
expectancy [7]. Thus, improving physical activity repre-
sents the best approach to address both pulmonary and
systemic manifestations of the disease [8].
Endurance time during high-intensity constant-load erg-
ometer exercise protocols (i.e. 75–80% peak work-rate) is
currently used to assess the effects of pharmacological and
non-pharmacological interventions, as it has proven to be
more sensitive than other procedures [9]. Importantly, en-
durance test is also listed as a suitable outcome for pivotal
trials with pharmacological interventions by regulatory
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bodies, e.g. the Food and Drug Administration (FDA) and
the European Medicines Agency (EMA), although no label
claim for improvements in exercise capacity has been
granted this far [10, 11]. Moreover, this approach
allows an evaluation of symptoms intensity (e.g.,
dyspnea and leg effort), or physiological variables
(e.g., inspiratory capacity, IC, assessment of dynamic
hyperinflation) at a standardized time (isotime), which
has been proved very useful in identifying the under-
lying physiological mechanisms responsible for modi-
fications in exercise tolerance induced by a particular
intervention [12].
In COPD exercise capacity can be improved by re-
habilitative interventions [13], as well as interventions
aimed at unloading the respiratory system, such as
breathing heliox (i.e.) [14], oxygen therapy [15], or non-
invasive ventilatory support [16], and recently high flow
nasal cannula [17]. However, the first-line treatment for
all COPD patients, after smoking cessation, remains
pharmacological, mainly with inhaled medication. Long-
acting bronchodilators represent the cornerstone of
COPD pharmacological therapy [18, 19]. Long-acting
muscarinic antagonists (LAMA), β2-agonists (LABA),
alone or in combination with inhaled steroids (ICS), and
the recent LABA/LAMA fixed-dose combinations
(FDCs), have been evaluated to assess their efficacy on
exercise capacity [8]. Despite the availability of studies
on LABA, LAMA, and ICS/LABA or LABA/LAMA
FDCs on exercise capacity, evidence for the efficacy of
bronchodilators in enhancing the exercise capacity of
patients with COPD is sometimes contradictory [20],
with, for instance, a recent trial which failed to demon-
strate the superiority of a LABA/LAMA FDC vs. placebo
[21]; moreover, current literature is characterized by a
large heterogeneity of studies, due to differences in
terms of inclusion criteria (unselected patients vs. COPD
patients with evidence of hyperinflation), and/or exercise
methodology (cycling vs. walking, cycle or treadmill
ergometer vs. shuttle walking test).
On this basis, we carried out a systematic review
and meta-analysis on the available clinical evidence to
evaluate the efficacy of long-acting bronchodilators
(altogether, and by single classes) on exercise capacity,
dynamic hyperinflation, and dyspnea during exercise
using high-intensity constant-load exercise test both
in unselected patients and in patients with demon-
strated lung hyperinflation at rest, and in studies with
different exercise methodologies (walking vs. cycling).
Methods
This systematic review and meta-analysis was con-
ducted according to the guidelines of the Preferred
Reporting Items for Systematic Reviews and Meta-
Analysis Protocols (PRISMA-P) statement [22].
Search strategy
We selected randomized controlled studies (RCTs)
focused on the efficacy of long-acting bronchodilators
(i.e.: LABA, LAMA, LABA/ICS, and LABA/LAMA
FDCs) on exercise capacity in COPD patients based on
endurance time with high-intensity constant-load per-
formed on a cycle or treadmill and whose duration was
longer than one week. We searched in PubMed and
EMBASE through September 2017. The following
keywords and their related MeSH (Medical Subjects
Heading) terms were used: “chronic obstructive pulmon-
ary disease”, “COPD”, “bronchodilator”, “long-acting
bronchodilator”, “LABAs”, “LAMAs”, “cardiopulmonary
exercise test”, “endurance time”, and “exercise”. Only
publications in English language were considered.
Studies selection and data extraction and study quality
assessment
We included RCTs focused on COPD patients (any level
of severity) which assessed as a primary or secondary
outcome the efficacy of long-acting bronchodilators on
exercise capacity evaluated by “endurance time” using
high-intensity constant-load ergometer exercise test, or
shuttle walking test, providing the results of active drugs
and placebo and not only between-arms difference. The
shuttle walking test uses an audio signal from a tape cas-
sette to direct the walking pace of the patient back and
forth on a 10-m course. Test ends when the patient can-
not reach the turnaround point within the required time
[12]. We included studies which used cycling or walking.
In both cases maximal exercise capacity was measured
using incremental symptom limited exercise test. Subse-
quently, constant-load (cycling or walking at 75–90% of
maximal work load) cycling ergometer or shuttle walk-
ing test (ESWT) were used to compare the efficacy of
active drugs with placebo. The following exclusion
criteria were chosen: 1) manuscripts focused on short-
acting bronchodilators, or not including placebo; 2) ex-
ercise capacity assessment based on a protocol different
from high-intensity constant load exercise test; 3) epi-
demiological observational study design or experimental
design other than RCT; 4) manuscripts not written in
English language; 5) data expressed only as difference vs.
placebo and not as single arms (active drugs and pla-
cebo). Two independent authors (MAR and FDM) firstly
reviewed all titles/abstracts to identify potentially rele-
vant articles. Then, study selection, based on a full-text
review, was performed according to the predefined
inclusion/exclusion criteria and disagreements were
resolved by consensus. The same authors reviewed eli-
gible studies using the CONSORT quality standard,
judged the studies quality by Jadad scale [23, 24], and
the risk of bias by a domain-based evaluation, which in-
cluded the following domains: sequence generation,
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allocation concealment, blinding of participants and
personnel, blinding of outcome assessment, attrition, se-
lective reporting bias and other sources of bias. Explicit
judgments were made about the overall risk of bias ac-
cording to the Cochrane guidance [25].
Endpoints
The primary endpoint was to assess the efficacy of all
long-acting bronchodilators (i.e.: LABA, LAMA, LABA/
ICS FDCs, and LABA/LAMA FDCs) vs. placebo on en-
durance time. The secondary endpoints were to investi-
gate the role of the above-mentioned drugs on IC and
dyspnea, as well as the comparison between drug classes
in terms of endurance time, IC, and dyspnea.
Statistical analysis
Forest plots were created to graphically assess both the
variability of the sample estimates and the weight of
sample sizes in the computation of estimates (weighted
means). A random-effects meta-analysis was carried out
to account for the presumed high between-study vari-
ability. Inconsistency among studies was assessed by the
I2 statistic to underscore the effect of true variability on
the overall variation. Since the inclusion criteria of the
studies in this field sometimes include the presence of
hyperinflation (i.e. FRC > 120%) a subgroup analysis was
carried out; furthermore, sub-analyses of the endurance
time were performed according to the exercise method-
ology (i.e. cycling vs. walking). Funnel plots and their
related Egger’s tests were performed to visually assess
the risk of bias, particularly publication and small
sample bias. Correlation between endurance time and
change in relevant physiological variables was under-
taken. The statistical software used were Stata13.0
(StataCorp, College Station, TX, USA) and StatsDirect
2.8.0, version 1.4 (StatsDirect Ltd., Altrincham, UK).
Results
Out of 88 potentially relevant studies, 22 (25%) were
deemed eligible for a qualitative and quantitative analysis
(Fig. 1); their characteristics are summarized in Table 1
[21, 26–44]. The efficacy of LABA, LAMA, LABA/
LAMA FDCs, and ICS/LABA FDCs as main treatment
was assessed in 6 (27%), 10 (45%), 3 (14%), and 3 (14%)
studies, respectively, with 5 (23%) studies using another
active drug as control of the experimental arm (Table 1).
The study design was cross-over in the majority of the
cases (15 studies, 68%). Endurance time was the most
frequently adopted primary outcome, followed by
pulmonary function; mean duration of treatment was
8.9 ± 15.9 weeks. The methodology used for exercise and
the intensity of the constant workload are reported in
Table 1; in most cases cycle ergometer exercise testing
was performed at 75–90% of maximal work load. The
BORG scale was used to evaluate dyspnea in all studies.
Characteristics of the enrolled patients are reported in
Table 2. Total sample size included 2898 patients; 65.4 ±
9.1% of which were males, with a mean age (mean SD)
Fig. 1 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram
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Table 1 Characteristics of selected studies
Author,
year
Country Study
design
Main treatment Other active
drugs
Duration
(weeks)
Primary outcome Secondary
outcomes
Exercise
methodology
and intensity
Man WDC,
2004
UK Crossover Salmeterol 50
μg bid
– 2 Transdiaphragmatic
pressure
Endurance time.
Pulmonary function,
dyspnoea
Treadmill,
80% W
O’Donnell
DE, 2004
Canada Crossover Salmeterol 50
μg bid
– 2 Pulmonary function
and dyspnoea
Endurance time Bike, 75% W
Neder JA,
2007
Brazil, UK Crossover Formoterol 12
μg bid
– 2 Endurance time Pulmonary function,
dyspnoea
Bike 80%, W
Beeh KM,
2011
Germany, UK Crossover Indacaterol
300 μg od
– 2 Pulmonary function Endurance time,
dyspnoea
Bike 80%, W
O’Donnell
DE, 2011
Canada, Belgium,
Spain, USA, UK
Crossover Indacaterol
300 μg od
– 3 Endurance time Pulmonary function,
dyspnoea
Bike 75%, W
Maltais F,
2016
Germany Crossover Olodaterol 5,
10 μg
– 6 Endurance time Pulmonary function,
dyspnoea
Bike 75%, W
O’Donnell
DE, 2004
Canada,
Germany, USA
Parallel Tiotropium 18
μg od
– 6 Endurance time Pulmonary function,
dyspnoea
Bike 75%, W
Casaburi
R, 2005
USA Parallel Tiotropium 18
μg od
– 25 Endurance time Pulmonary function,
dyspnoea
Treadmill,
80% W
Maltais F,
2005
Canada, USA Parallel Tiotropium 18
μg od
– 6 Endurance time Pulmonary function,
dyspnoea
Bike, 75% W
Travers J,
2007
Canada, USA Crossover Tiotropium 18
μg od
– 1 Cardiopulmonary
function
Endurance time Bike, 75% W
Maltais F,
2011
Canada, USA,
Spain
Parallel Aclidinium
200 μg od
– 6 Endurance time Pulmonary function,
dyspnoea
Bike, 75% W
Beeh KM,
2012
Germany, UK,
Switzerland
Crossover Glycopyrronium
50 μg od
– 3 Endurance time Pulmonary function,
dyspnoea
Bike, 80% W
Cooper CB,
2013
USA, UK, Brazil Parallel Tiotropium 18
μg od
– 96 Endurance time Pulmonary function,
dyspnoea
Treadmill
90% Wa
Beeh KM,
2014
Germany Crossover Aclidinium
400 μg bid
– 3 Endurance time Pulmonary function,
dyspnoea
Bike, 75% W
Casaburi
R, 2014
USA, Canada Crossover Tiotropium 18
μg od
– 6 IC isotime Endurance time,
Borg isotime
Treadmill,
80% Wa
Bedard
M-E, 2012
Canada Parallel Tiotropium 18
μg od
– 3 Endurance time Pulmonary function,
dyspnoea
ESWT, 80%
VO2
Beeh KM,
2014
Germany, UK,
USA
Crossover Indacaterol/
Glycopyrronium
110/50 μg od
Tiotropium
18 μg od
3 Endurance time Pulmonary function,
dyspnoea
Bike, 75% W
Maltais F,
2014
Germany Crossover Umeclidinium/
vilanterol 125/25,
62,5/25 μg
Vilanterol 25 μg,
Umeclidinium
62,5, 125 μg
12 Endurance time,
trough FEV1
Pulmonary function ESWT, 80–
90% speed
O’Donnell,
2017
Crossover Tiotropium/
Olodaterol, 5/2,5,
5/5 μg
Tiotropium 5 μg,
Olodaterol 5 μg
6 Endurance time,
inspiratory capacity
Pulmonary function,
dyspnea
Bike, 75% W
O’Donnell
DE, 2006
Canada, USA Parallel Salmeterol 50 μg/
Fluticasone 250
μg bid
Salmeterol
50 μg bid
8 Pulmonary function
and dyspnoea
Endurance time Bike, 75% W
Worth H,
2010
Germany,
Sweden
Crossover Budesonide/
formoterol 320/9
μg bid
Formoterol 9
μg bid
1 Endurance time Pulmonary function,
dyspnea
Bike, 75% W
Guenette
JA, 2013
Canada Crossover Fluticasone 250/
Salmeterol 50
μg bid
– 6 Endurance time Pulmonary function,
dyspnoea
Bike, 85% W
Od Once daily, Bid Twice daily, ESWT Endurance shuttle walking test, W Work load. aWork rate was adjusted to obtain an exercise duration between a specified
time interval
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of 62.9 (7.7) years, BMI of 26.7 (4.4) Kg/m2, basal
FEV1 of 50.3 (11.5)% of predicted value, and a basal
inspiratory capacity of 78.4 (19.7) % of predicted
value. Weighted mean increase of trough FEV1 and
trough IC following the exposure to all long-acting
bronchodilators (end of the study) selected in out
meta-analysis resulted of 144 ml (95% CI ranges from
126 to 162; I2: 73.4% treatment arms: 40), and of
157 ml (95% CI ranges from 138 to 175; I2: 34.8%
treatment arms: 30), respectively.
Table 2 Characteristics of patients enrolled in studies selected for the final analysis
Author, year Main treatment Inclusion criteria Numbers of
individuals
randomized
Number available
for the final
analysis
Male, % Age, yrs BMI,
Kg/m2
Basal FEV1, %
Man WDC, 2004 Salmeterol 50 μg bid FEV1 change post bd
< 10% and 200 ml
20 16 63 68 (7.6) – 31.1 (3.9)
O’Donnell DE, 2004 Salmeterol 50 μg bid FEV1 ≤ 70%, FRC ≥ 120%,
BDI ≤ 6
23 23 65 64 (2.0) 26.1 (0.8) 42 (−)
Neder JA, 2007 Formoterol 12 μg bid FEV1/FVC ≤ 60%, FEV1 < 60%
and change after bd < 12%
21 18 67 42–75
(range)
24.8 (5.1) 38.8 (11.7)
Beeh KM, 2011 Indacaterol 300 μg od 40–80 yrs., 80% ≥ FEV1 ≥ 40%,
FRC≥ 120%
27 24 67 61.3 (7.2) 25.6 (3.4) 51.5 (11.4)
O’Donnell DE, 2011 Indacaterol 300 μg od ≥40 yrs., 80%≥ FEV1 ≥ 30% 90 74 70 62.8 (8.2) 27.5 (4.1) 61 (12.4)
Maltais F,
2016
Study
1222.37
Olodaterol 5, 10 μg 40–75 yrs., FEV1 < 80% 151 140 77 60.6 (7.7) – 48.5 (14.5)
Study
1222.38
157 141 74 60.6 (7.7) – 51.6 (14.2)
O’Donnell DE, 2004 Tiotropium 18 μg od 40–70 yrs., FEV1≤ 65%,
FRC≥ 120%
198 187 74 60.5 (−) 26.5 (4.8) 44 (13.0)
Casaburi R, 2005 Tiotropium 18 μg od ≥40 yrs., FEV1 ≤ 60% 108 91 57 66.6 (7.9) 25.9 (5.2) 34.4 (12.4)
Maltais F, 2005 Tiotropium 18 μg od 40–75 yrs., FEV1≤ 65%,
FRC≥ 120%
261 241 72 62.5 (7.4) – 43.1 (12.7)
Travers J, 2007 Tiotropium 18 μg od FEV1 ≤ 65%, FRC ≥ 120%,
BDI ≤ 6
– 18 72 60 (9.0) 26.8 (5.4) 40 (−)
Maltais F, 2011 Aclidinium 200 μg od ≥40 yrs., 80%≥ FEV1 ≥ 30%,
FRC≥ 120%, BDI ≤ 7
181 159 52 64.8 (−) 26.4 (−) 50 (−)
Beeh KM, 2012 Glycopyrronium 50 μg od ≥40 yrs., 80%≥ FEV1 ≥ 40% 108 95 58 60.5 (8.6) 26.6 (4.0) 57.1 (8.5)
Cooper CB, 2013 Tiotropium 18 μg od ≥40 yrs., FEV1 ≤ 65%,
mMRC≥2
519 464 77 65 (−) 26.4 (−) 44 (12.0)
Beeh KM, 2014 Aclidinium 400 μg bid ≥40 yrs., 80%≥ FEV1 ≥ 30%,
FRC≥ 120%
112 106 68 60.3 (8.1) – 56.7 (11.6)
Casaburi R, 2014 Tiotropium 18 μg od ≥40 yrs., FEV1 ≥ 50%, 35 ≥
BMI ≥ 18 Kg/m2, BDI ≤ 9
126 111 52 61.2 (8.8) 27.8 (3.9) 70 (17.0)
Bedard M-E, 2012 Tiotropium 18 μg od ≥50 yrs., FEV1 < 70% 36 34 68 65 (7) 28 (4) 54 (12)
Beeh KM, 2014 Indacaterol/
Glycopyrronium 110/
50 μg od
≥40 yrs., 70%≥ FEV1 ≥ 40% 85 73 63 62.1 (8.1) – 56 (8.9)
Maltais F,
2014
Study
417
Umeclidinium/vilanterol
125/25, 62,5/25 μg
≥40 yrs., 70%≥ FEV1 ≥ 35%,
FRC≥ 120%, mMRC≥2
349 348 56 61.6 (8.3) – 51.3 (9.7)
Study
418
308 307 55 62.6 (7.9) – 51.3 (10.0)
O’Donnell,
2017
Mor 1 Olodaterol/Tiotropium
2,5/5, 5/5 μg
40–75 yrs., 80% ≥ FEV1 ≥ 30% 295 227 72 62.2 (7.5) 27.3 (5.3) 52.6 (13.9)
Mor 2 291 224 70 61.2 (7.9) 26.7 (4.6) 52.0 (13.4)
O’Donnell DE, 2006 Salmeterol 50 μg/
Fluticasone 250 μg bid
≥40 yrs., FEV1 < 70%,
FRC≥ 120%, BDI < 7,
≥20 W at CPET
123 117 70 64 (−) 25.9 (−) 41 (−)
Worth H, 2010 Budesonide/formoterol
320/9 μg bid
≥exacerbation last 1 yr.,
FEV1 ≤ 50%, FRC > 120%
111 91 76 63.7 (−) 25.7 (−) 37 (8.4)
Guenette JA, 2013 Fluticasone 250/
Salmeterol 50 μg bid
≥40 yrs., FEV1 > 60% 18 15 40 64 (10.0) 29.5 (6.4) 86 (15.0)
Od Once daily, bid Twice daily, bd Bronchodilation, Mor MORACTO study
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The median Jadad score for the RCTs included in our
analysis was 4 (range 4–5); a detailed assessment of the
risk of bias is described in the supplement materials
using the Cochrane collaboration tool for assessing risk
of bias. The risk of bias was deemed low for the majority
of the items in the selected studies. No relevant asym-
metries were found in several funnel plots related to the
main clinical variables.
Efficacy of long-acting bronchodilators on ET, inspiratory
capacity, and dyspnea during exercise
Figure 2 illustrates a weighted mean increase in endurance
time following the exposure to long-acting bronchodilators
of 67 s (95% CI ranges from 55 to 79; I2: 22.1%, computed
on 34 treatment arms). The role played by long-acting
bronchodilators on isotime IC and dyspnea is summarized
in Figs. 3, and 4, respectively: weighted means were 195 ml
(95% CI ranges from 162 to 229; I2: 1.2%; treatment arms:
20), and − 0.41 units (95% CI ranges from − 0.56 to − 0.27;
I2: 55.1%; treatment arms: 30), respectively.
Efficacy of different classes of long-acting bronchodilators
Figure 5 shows the efficacy of different classes of long-
acting bronchodilators at approved doses for COPD
treatment in terms of endurance time, isotime IC, and
dyspnea. This analysis did not show any significant
Fig. 2 Efficacy of long-acting bronchodilators on endurance time. I2 21.1% (95% CI 0–48.8%). Error bars represent 95% confidence intervals. †:
study n. 1222.37; *: study n. 1222.38
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differences among the investigated categories of long-
acting bronchodilators; however, for endurance time the
efficacy of LABA seems lower than for other classes.
Efficacy of long-acting bronchodilators in patients with
hyperinflation and using different exercise methodologies
To better understand the role of hyperinflation at rest
we performed a prespecified subgroup analysis focused
on the 11 studies which reported a value of FRC > 120%
as inclusion criterion (Table 2). In this subgroup of stud-
ies, mean change of trough FEV1 following the exposure
to all long-acting bronchodilators (end of the study) re-
sulted of 153 ml (95% CI ranges from 123 to 183; I2:
73.8% treatment arms: 19), and mean change of trough
IC resulted of 154 ml (95% CI ranges from 121 to 187;
I2: 50.4% treatment arms: 18). Weighted mean change of
endurance time, inspiratory capacity, and dyspnea
following the exposure to long-acting bronchodilators
resulted of 94 s (95% CI ranges from 65 to 123; I2:
10.4%, computed on 11 treatment arms), 174 ml (95%
CI ranges from 131 to 216; I2: 0%; treatment arms: 14),
and − 0.37 units (95% CI ranges from − 0.54 to − 0.21;
I2: 53.2%; treatment arms: 18), respectively (Additional
file 1: Figure S2A). In the subgroup of the 11 studies
which did not require an increase of FRC as inclusion
criterion weighted mean change of endurance time, in-
spiratory capacity and dyspnea following the exposure to
long-acting bronchodilators resulted of 61 s (95% CI
ranges from 49 to 73; I2: 17.2%, computed on 23 treat-
ment arms), 231 ml (95% CI ranges from 178 to 285; I2:
0%; treatment arms: 6), and − 0.51 units (95% CI ranges
from − 0.80 to − 0.21; I2: 60.2%; treatment arms: 12), re-
spectively (Additional file 1: Figure S2B). We did not
find any significant correlations between ET and mean
trough FEV1 (rho: 0.38, P: 0.063), or between ET and
trough IC (rho: 0.14, P: 0.593).
In the subgroup of the 5 studies which used walking
as exercise methodology, weighted mean change of en-
durance time following the exposure to long-acting
bronchodilators resulted of 58 s (95% CI ranges from − 4
to 121; I2: 56.2%, computed on 5 treatment arms), com-
pared to 68 s (95% CI ranges from 56 to 79; I2: 13.3%,
computed on 29 treatment arms) in the studies which
used a cycle ergometry (Additional file 1: Figure S3).
Discussion
The main findings of this systematic review and meta-
analysis are: 1) long-acting bronchodilators are effective
in improving exercise capacity in COPD patients, with
an average increase of about 60 s; 2) this effect is
Fig. 3 Efficacy of long-acting bronchodilators on isotime inspiratory capacity. I2 1.2% (95% CI 0–42.8%). Error bars represent 95% confidence
intervals. *: study n. 417
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associated with a reduction of dyspnea during exercise;
3) the increase in isotime IC is similar to the change of
trough IC, and this is the reason why the effect seems
to be a decrease of basal inspiratory capacity rather
than a modification of dynamic hyperinflation during
exercise; 4) the use of LABA and LAMA is associated
with a similar improvement of exercise tolerance,
dynamic hyperinflation, and dyspnea; however, it is
possible to identify a trend in favour of LAMA in terms
of ET; 5) the efficacy of long-acting bronchodilators on
ET were higher in the studies which required an in-
crease of FRC as inclusion criterion; however we failed
to demonstrate a correlation between ET and trough
IC; 6) the efficacy of long-acting bronchodilators is
similar when walking or cycling are used as exercise
methods.
Maintenance therapy with long-acting bronchodilators
has been demonstrated to significantly reduce oper-
ational lung volumes during exercise in symptomatic
patients with COPD, even if this beneficial effect does
not always have an impact on exercise duration.
Casaburi R et al. found a significant effect of tiotropium
on exercise duration in COPD patients with moderate
(i.e. FEV1 < 80%), but not mild (i.e. FEV1 > 80%) disease
[40]. Our meta-analysis found that, on average, there is a
concordance between the increase of inspiratory cap-
acity, the improvement of exercise tolerance, and the re-
duction of dyspnea in patients with moderate to severe
COPD. Unfortunately, we are not able to extend these
findings to patients with mild disease, since most of the
studies we included in our analysis had enrolled patients
with FEV1 < 70% predicted value (Table 2), and also in
Fig. 4 Efficacy of long-acting bronchodilators on dyspnea. I2 55.1% (95% CI 26.8–69.4%). Error bars represent 95% confidence intervals. For Ume/
Vil †: study n. 1222.37; *: study n. 1222.38. For Olo †: study n. 418; *: study n. 417
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case of inclusion criteria permissive for milder disease,
results for patients with FEV1 > 80% were not available.
As previously discussed, we found a significantly higher
improvement in ET, of about 50%, in the studies which
required an increase of FRC as inclusion criterion; this
result could demonstrate that long-acting bronchodila-
tors are more effective in terms of exercise capacity in
COPD patients with lung hyperinflation. Thus, even if
we found that the improvement of operational lung vol-
ume is correlated with the increase of ET after broncho-
dilation, we failed to demonstrate a correlation between
trough IC and ET per se, result which could suggest
that, even if hyperinflation is a crucial aspect for exercise
limitation in COPD, the absolute value of ET depends
on many factors.
We did not find any significant difference in terms of
endurance time, dynamic hyperinflation, and symptoms
during exercise between LABA and LAMA, the two
classes of long-acting bronchodilators most studied in
these fields; however, a trend in favor of LAMA was
identifiable at least in terms of endurance time. It’s to
notice that the present study does not allow to explain
why LAMA could be superior of LABA in terms of exer-
cise capacity. Beta-2 agonists and antimuscarinic agents
could theoretically exert a different efficacy on exercise
capacity due to differences in the distribution of recep-
tors, both in and outside the lung, and in mechanism of
action. Indeed, beta-2 adrenergic receptors are present
in high density not only in airway smooth muscle cells,
but also in vascular endothelium, ciliated cells, circulating
inflammatory cells, such as eosinophils, and sub-mucosal
glands. On the other hand, muscarinic receptors are
present on bronchial smooth muscle cells, parasympathetic
and sympathetic nerves, ganglia cells, mucus secreting cells,
and inflammatory cells. ICS/LABA FDCs have proved to be
more effective than LABA alone in terms of function,
Fig. 5 Efficacy of different classes of long-acting bronchodilators tested at the approved dose for COPD treatment. Error bars represent 95%
confidence intervals
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quality of life, symptoms and prevention of exacerbations
[45]. Therefore, even if the efficacy on FEV1 cannot be dir-
ectly translated to lung deflation (a crucial determinant of
exercise capacity on COPD), there is a rationale to expect a
better efficacy of ICS/LABA FDCs rather than LABA alone
on exercise capacity. The same, and probably with major
emphasis, has to be expected for LABA/LAMA combina-
tions, which confirmed to be more effective in terms of
function and symptoms than not only LABA or LAMA
alone, but also ISC/LABA FDCs [46, 47]. Even if some of
the studies currently available failed to demonstrate a
superiority of LABA/LAMA compared with mono-
components [21, 41], in a recent meta-analysis LABA/
LAMA FDCs were found to be more effective than LABA
or LAMA alone in terms of ET [48]. There is limited infor-
mation on minimum clinically significant differences for
endurance time after an intervention [49]. In COPD, a
105 s change from baseline using cycle ergometry related
well with positive patient-reported outcomes after pulmon-
ary rehabilitation [50, 51]. However, data from bronchodila-
tor studies suggest that improvements in lung function that
seem to be clinically important are often associated with in-
creases in endurance time of 60 s [49]. For dyspnea (isotime
Borg) and IC at isotime, the minimal clinically important
difference (MCID) were suggested to be 1 unit, and 200 ml,
respectively [49]. Our meta-analysis found a weighted mean
change, following the exposure to long-acting bronchodila-
tors, of endurance time, dyspnea, and IC at isotime of 67 s,
− 0.41 units, and 195 ml, respectively. These improvements
we found are higher than the MCID for endurance time,
probably the most important outcome, borderline clinically
significant for dynamic hyperinflation during exercise, but
far from the MCID for dyspnea. The average improvement
we found is similar to that obtained by oxygen in mildly
or nonhypoxaemic COPD patients who are dyspnoeic
at rest [52]. It is noteworthy that, as pointed out by
Puente-Maestu et al. in a recent ERS statement, non-
pharmacological interventions, such as rehabilitation,
Heliox, oxygen in hypoxaemic patients and noninvasive
ventilation, have demonstrated significantly higher en-
durance time increases [49]. However, pharmacological
and nonpharmacological treatments of COPD are not mu-
tually exclusive, since the former have to be considered in
all cases, and their combination has shown to be more
convenient that a single approach [33]. Moreover, the
evaluation of variables at isotime is sometimes problem-
atic since they are often extrapolated or interpolated.
Finally, we found a similar efficacy of long-acting bron-
chodilators when walking or cycling are used as exercise
methodologies. The main reason why the sub-analysis of
the 5 studies which used walking as exercise methodology
failed to demonstrate a statistically significant efficacy vs.
placebo is probably due to the low power of the analysis,
with an average difference similar to that of the studies
which used cycle ergometer (58 vs. 68 s). This result, im-
portant since “walking” is evidently the most common
real-life exercise of COPD patients, confirms a previous
study, which demonstrated a similar efficacy of formoterol
on endurance time evaluated by walking and cycling [53].
A number of potential limitations of the study deserves
discussion. Firstly, the studies we included in this meta-
analysis present different inclusion criteria for COPD
patients who, in most but not all studies, were requested
to present a significant hyperinflation (e.g. FRC > 120% of
predicted values); this could limit the external validity of
our analysis, since the main indication of long-acting
bronchodilators is so far COPD per se (i.e. FEV1/FVC <
lower limit of normal) without the need of hyperinflation.
However, a specific analysis including the studies which
requested an increase of FRC as inclusion criterion was
performed, with evidence of a higher efficacy of long-
acting bronchodilators when compared with the studies
which evaluated unselected COPD patients. Secondly, the
duration of the studies we included in our analysis was
very heterogeneous, ranging from one to 96 weeks, with
an average duration of the treatment of 9.6 weeks. Prob-
ably depending on the onset of action, some drugs dem-
onstrated to be able to improve endurance time
immediately after the first inhalation [29]; however, due to
the chronic nature of the disease and the consequent long
treatment course, this aspect is not so clinically relevant,
and a significant effect expected in “some” weeks is the
message which emerges from our analysis. Then, we de-
cided to include ICS/LABA combination in the analysis,
since this treatment is very common in clinical practice.
The addition of ICS to LABA can be a confounder for the
interpretation of the effect of long-acting bronchodilators
on exercise capacity. However, the subgroups analysis ac-
cording to treatment classes (LABA; LAMA, ICS/LABA,
and LABA/LAMA) allows to evaluate the effects of bron-
chodilators alone, confirming the efficacy of these treat-
ment without ICS. Finally, the changes we found of
isotime IC are close to those of trough IC, suggesting that
the main effect of long-acting bronchodilators is an in-
crease in basal inspiratory capacity rather than a modifica-
tion of dynamic hyperinflation during exercise (i.e. the
slope of change of IC).
Conclusion
Long-acting bronchodilators improve exercise capacity
in COPD patients, with an average change higher than
the minimum clinically significant difference. While
long-acting bronchodilators consistently improve the
capacity to tolerate exercise by improving lung mechan-
ics, the challenge remains to convert this advantage into
increased habitual physical activity. An additional behav-
ioral intervention will likely be needed to achieve this in
the hope of improving long-term survival [8].
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